Joe Rogan Experience #2553 - Andrew Hubermsan · Aired Sep 14, 2026
Claim summary · not a verbatim quotation
GLP-1 drugs increase GLP-1 levels by a thousandfold to suppress appetite.
The finding
What the evidence shows
These drugs do not raise your own GLP-1. Semaglutide is a synthetic stand-in that sits in the blood around 16 to 30 nmol/L at standard weekly doses, against natural GLP-1 levels near 10 to 20 pmol/L, which is where a thousandfold comes from. The problem is that the FDA label states more than 99 percent of semaglutide is bound to a blood protein called albumin, so the free drug that can actually reach the receptor is far lower, closer to tens of times the natural level, and it is a somewhat weaker activator than the body's own GLP-1. Comparing total drug in the blood against free natural hormone makes the gap look bigger than it is.
Read the supporting source · dailymed.nlm.nih.gov ↗Quick answer & review status
Quick answer
Is it true that GLP-1 drugs increase GLP-1 levels by a thousandfold to suppress appetite?
Partly. The claim stretches what the evidence shows. These drugs do not raise your own GLP-1. Semaglutide is a synthetic stand-in that sits in the blood around 16 to 30 nmol/L at standard weekly doses, against natural GLP-1 levels near 10 to 20 pmol/L, which is where a thousandfold comes from. Andrew Hubermsan said it (matched by voice) on Joe Rogan Experience #2553 - Andrew Hubermsan, aired Sep 14, 2026, at 1:53:48. The supporting source is dailymed.nlm.nih.gov, linked below.
The context belongs here.
No separately verified on-air correction is recorded for this check. That is not a claim that nobody corrected it.
- Attribution
- Not independently confirmed in this record
- Editorial context review
- Not recorded; generated finding
- Coverage
- One selected claim from the episode
Revisions to this check
No dated revision is recorded here. Older checks may predate this log.
Challenge this finding or add context →Keep the evidence coming.
Follow new checks in your RSS reader, or catch up with the weekly briefing on the site.
Email signup is currently unavailable.
Prefer to catch up here? Read the weekly briefing.